Nexiam 40 40 mg Powder for solution for injection and infusion.
PDF Leaflet Revision Date: 25 November 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of gastro-oesophageal reflux disease and prevention of rebleeding in ulcers.
Dosage (summary)
40 mg IV once daily for GORD; 80 mg bolus for rebleeding, then 8 mg/hr infusion.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Limited data in pregnancy; not recommended during breastfeeding.
Key Drug Interactions
- Clopidogrel
- Warfarin
- Digoxin
- Atazanavir
- Nelfinavir
Contraindications
- Hypersensitivity to esomeprazole
- Concomitant use with atazanavir or nelfinavir
Common side effects
- Headache
- Abdominal pain
- Diarrhoea
- Nausea
Counselling Points
- Monitor for severe skin reactions
- Avoid use with clopidogrel
- Consider magnesium levels during long-term use
Serious warnings
- Serious cutaneous adverse reactions
- Risk of hypomagnesaemia
- Increased risk of gastrointestinal infections
Important Disclaimer
The Nexiam 40 40 mg Powder for solution for injection and infusion. professional information leaflet below is the property of Astrazeneca Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
